Reported 29 days ago
Pharmaceutical companies are investing over $250 billion in US manufacturing to align with Trump's tariff strategy, with major commitments from AstraZeneca, Johnson & Johnson, and Eli Lilly. However, experts warn that these investments may not significantly reduce reliance on foreign drug supplies or lower drug prices for American consumers, and the complexity of the pharmaceutical supply chain complicates the impact of potential tariffs.
Source: YAHOO